Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Medicenna to Present at Bloom Burton & Co. Healthcare Investor Conference 2018

Medicenna Therapeutics
Posted on: 26 Apr 18

TORONTO and HOUSTON, April 25, 2018 /PRNewswire/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; OTCQX: MDNAF), a clinical stage immuno-oncology company, is pleased to announce that executives from Medicenna, Dr. Fahar Merchant, Chairman, President and CEO and Ms. Elizabeth Williams, CFO, will present an overview of the Company at the Bloom Burton & Co. Healthcare Investor Conference.

Details of the presentation are as follows:

Date: 

 Wednesday, May 2, 2018

Time: 

 11:00 am ET

Location: 

 Hall B, Lower Concourse Level of the Sheraton Centre Toronto Hotel, Toronto, Canada

About the Conference:
The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings.

About Medicenna Therapeutics
Medicenna is a clinical stage immuno-oncology company developing novel highly selective versions of IL-2, IL-4 and IL-13 Superkines™ and first in class Empowered Cytokines™ (ECs).  Medicenna is specifically targeting the Interleukin-4 Receptor (IL4R), which is over-expressed by at least 20 different types of cancer affecting more than one million new cancer patients every year. A Phase 2b clinical trial for recurrent glioblastoma (rGBM) is enrolling patients at leading brain cancer centres in the US using Medicenna's lead candidate MDNA55. MDNA55 has completed 3 clinical trials in 72 patients, including 66 adults with rGBM, demonstrated compelling efficacy and obtained Fast-Track and Orphan Drug status from USFDA. Unlike most other cancer therapies, Medicenna's MDNA55 has the potential to purge both the tumor and the immunosuppressive tumor microenvironment, offering a unique treatment paradigm for a large majority of cancer patients.

For more information, please visit www.medicenna.com.

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 26/04/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.